![Bryan Irving](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bryan Irving
Corporate Officer/Principal presso
3T Biosciences, Inc.
Profilo
Bryan A Irving is currently the Chief Scientific Officer at 3T Biosciences, Inc. He previously worked as a Senior Advisor at Frazier Management LLC, Chief Scientific Officer & Executive VP at Five Prime Therapeutics, Inc., Vice President & Cancer Immunology at CytomX Therapeutics Holdings LLC, and Chief Scientific Officer at Amunix Pharmaceuticals, Inc. Dr. Irving received his undergraduate degree from the University of California, Berkeley and his doctorate from The University of California, San Francisco.
Posizioni attive di Bryan Irving
| Società | Posizione | Inizio |
|---|---|---|
3T Biosciences, Inc.
 3T Biosciences, Inc. BiotechnologyHealth Technology Operates as an immunotherapy company that develops next-generation and transformative therapies for the treatment of solid tumors and immune-mediated diseases | Corporate Officer/Principal | 01/10/2023 |
Precedenti posizioni note di Bryan Irving
| Società | Posizione | Fine |
|---|---|---|
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer | Corporate Officer/Principal | 01/07/2022 |
| FIVE PRIME THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 30/05/2019 |
CytomX Therapeutics Holdings LLC
 CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology Engaged in the development of new generation targeted antibody therapeutics | Investitore di Private Equity | 01/08/2017 |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Consulente / Consigliere | - |
Formazione di Bryan Irving
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
31
Relazioni di 1° grado
7
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Finance |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology Engaged in the development of new generation targeted antibody therapeutics | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer | Health Technology |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology Operates as an immunotherapy company that develops next-generation and transformative therapies for the treatment of solid tumors and immune-mediated diseases | Health Technology |
